inclusion criteria: 1. informed consent prior to performing study procedures (witnessed oral consent with written consent by representatives will be accepted to avoid paper handling). written consent by patient or representatives will be obtained whenever possible. 2. adult patients ≥18 years of age at the time of enrolment. 3. laboratory-confirmed sars-cov-2 infection as determined by pcr, in oropharyngeal swabs or any other relevant specimen obtained during the course of the disease. alternative tests (e.g., rapid antigenic tests) are also acceptable as laboratory confirmation if their specificity has been accepted by the sponsor. 4. moderate to severe ards (pao2/fio2 ratio equal or less than 200 mmhg) for less than 96 hours at the time of randomization. 5. patients requiring invasive ventilation are eligible within 72 hours from intubation. 6. eligible for icu admission, according to the clinical team.

inclusion criteria: 1. informed consent prior to performing study procedures (witnessed oral consent with written consent by representatives will be accepted to avoid paper handling). written consent by patient or representatives will be obtained whenever possible. 2. adult patients ≥18 years of age at the time of enrolment. 3. laboratory-confirmed sars-cov-2 infection as determined by pcr, in oropharyngeal swabs or any other relevant specimen obtained during the course of the disease. alternative tests (e.g., rapid antigenic tests) are also acceptable as laboratory confirmation if their specificity has been accepted by the sponsor. 4. moderate to severe ards (pao2/fio2 ratio equal or less than 200 mmhg) for less than 96 hours at the time of randomization. 5. patients requiring invasive ventilation are eligible within 72 hours from intubation. 6. eligible for icu admission, according to the clinical team.

inclusion criteria: informed consent prior to performing study procedures (witnessed oral consent with written consent by representatives will be accepted to avoid paper handling). written consent by patient or representatives will be obtained whenever possible. adult patients ≥18 years of age at the time of enrolment. laboratory-confirmed sars-cov-2 infection as determined by pcr, in oropharyngeal swabs or any other relevant specimen obtained during the course of the disease. alternative tests (e.g., rapid antigenic tests) are also acceptable as laboratory confirmation if their specificity has been accepted by the sponsor. moderate to severe ards (pao2/fio2 ratio equal or less than 200 mmhg) for less than 96 hours at the time of randomization. patients requiring invasive ventilation are eligible within 72 hours from intubation. eligible for icu admission, according to the clinical team.

inclusion criteria: informed consent prior to performing study procedures (witnessed oral consent with written consent by representatives will be accepted to avoid paper handling). written consent by patient or representatives will be obtained whenever possible. adult patients ≥18 years of age at the time of enrolment. laboratory-confirmed sars-cov-2 infection as determined by pcr, in oropharyngeal swabs or any other relevant specimen obtained during the course of the disease. alternative tests (e.g., rapid antigenic tests) are also acceptable as laboratory confirmation if their specificity has been accepted by the sponsor. moderate to severe ards (pao2/fio2 ratio equal or less than 200 mmhg) for less than 96 hours at the time of randomization. patients requiring invasive ventilation are eligible within 72 hours from intubation. eligible for icu admission, according to the clinical team.

inclusion criteria: 1. informed consent prior to performing study procedures (witnessed oral consent with written consent by representatives will be accepted to avoid paper handling). written consent by patient or representatives will be obtained whenever possible. 2. adult patients ≥18 years of age at the time of enrolment. 3. laboratory-confirmed sars-cov-2 infection as determined by pcr, in oropharyngeal swabs or any other relevant specimen obtained during the course of the disease. alternative tests (e.g., rapid antigenic tests) are also acceptable as laboratory confirmation if their specificity has been accepted by the sponsor. 4. moderate to severe ards (pao2/fio2 ratio equal or less than 200 mmhg) for less than 96 hours at the time of randomization. 5. patients requiring invasive ventilation are eligible within 72 hours from intubation. 6. eligible for icu admission, according to the clinical team.

inclusion criteria: 1. informed consent prior to performing study procedures (witnessed oral consent with written consent by representatives will be accepted to avoid paper handling). written consent by patient or representatives will be obtained whenever possible. 2. adult patients ≥18 years of age at the time of enrolment. 3. laboratory-confirmed sars-cov-2 infection as determined by pcr, in oropharyngeal swabs or any other relevant specimen obtained during the course of the disease. alternative tests (e.g., rapid antigenic tests) are also acceptable as laboratory confirmation if their specificity has been accepted by the sponsor. 4. moderate to severe ards (pao2/fio2 ratio equal or less than 200 mmhg) for less than 96 hours at the time of randomization. 5. patients requiring invasive ventilation are eligible within 72 hours from intubation. 6. eligible for icu admission, according to the clinical team.